Argireline half-life & pharmacokinetics

Reported half-life

Not systemically pharmacokinetically relevant given the topical cosmetic use case. Percutaneous absorption to dermal-epidermal interface is the pharmacokinetic parameter of interest, achieved without fatty-acid modification (Argireline lacks the palmitoylation of Matrixyl but retains some penetration through its small hexapeptide size and specific residue composition).

The half-life and pharmacokinetic profile of Argireline reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Topical application (cosmetic and research standard route)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Synthetic hexapeptide cosmetic ingredient; SNAP-25 N-terminal mimetic that competitively disrupts SNARE complex formation; legal INCI-listed cosmetic ingredient in the UK.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Argireline acts as follows:

Argireline (acetyl hexapeptide-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) is a synthetic hexapeptide developed by Lipotec (Barcelona) as a topical cosmetic ingredient producing anti-wrinkle effects through disruption of the SNARE (Soluble N-ethylmaleimide-sensitive-factor Attachment REceptor) complex — the molecular machinery essential for neurotransmitter vesicle fusion at neuromuscular junctions and other synapses. The peptide sequence corresponds to the N-terminal region of SNAP-25 (synaptosomal-associated protein of 25 kDa), one of the three principal SNARE complex proteins. This is mechanistically the same target region cleaved by botulinum toxin type A — the pharmacological basis of Botox's muscle-paralysing effect.

See the full Argireline research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.